trending Market Intelligence /marketintelligence/en/news-insights/trending/A6WuRUVKjU86sRGDCAOsjA2 content esgSubNav
In This List

Tvardi Therapeutics names CEO

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Tvardi Therapeutics names CEO

Tvardi Therapeutics Inc. said it appointed Imran Alibhai as the company's CEO and board member, effective immediately.

Previously, Alibhai served as senior vice president and managing director at DNAtrix Inc. He was also an investment banker in PJ Solomon LP's healthcare advisory group. In addition, he held investing roles at Accelerator Corp., Alexandria Venture Investments LLC and MPM Capital.

Houston-based Tvardi Therapeutics is a biotechnology company that develops medicines for the treatment of cancer, chronic inflammation and fibrosis.